Healthcare Oct 19, 2021 06:11 PM (GMT+8) · EqualOcean
Cailian, October 19 (Xinhua) - Kanghong pharmaceutical announced that the company recently received the notice of approval for clinical trial of kh737 eye drops issued by the State Food and Drug Administration and agreed to carry out clinical trial. The active ingredient of the product mainly inhibits the growth of ocular axis by interacting with relevant receptors of retina and sclera, so as to delay the progress of myopia.